Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) to remain on ARTG

On 5th April, 2013 the Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.

The AAT’s decision was made after considering the evidence of scientific and medical experts put forward by both the Therapeutic Goods Administration and Aspen over the course of a week during 2012, and a further hearing in February 2013.

Aspen will provide further details of the conditions that will be implemented in further communications to Doctors and Pharmacists.

Doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.

Di-Gesic is available at retail pharmacies. Information on the availability of Doloxene, which is currently out of stock, will be provided shortly.

Di-Gesic Product Information

Doloxene Product Information